AbCellera Biologics (ABCL)
(Delayed Data from NSDQ)
$3.97 USD
+0.12 (3.12%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $3.98 +0.01 (0.25%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
AbCellera Biologics Inc. (ABCL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$15.78 | $28.00 | $8.00 | 293.52% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for AbCellera Biologics Inc. comes to $15.78. The forecasts range from a low of $8.00 to a high of $28.00. The average price target represents an increase of 293.52% from the last closing price of $4.01.
Analyst Price Targets (9 )
Broker Rating
AbCellera Biologics Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, 10 are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 10 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/12/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
4/1/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
2/23/2024 | Piper Sandler | Allison M Bratzel | Strong Buy | Strong Buy |
2/22/2024 | The Benchmark Company | Robert Wasserman | Hold | Strong Buy |
12/5/2023 | KeyBanc Capital Markets | Scott Schoenhaus | Strong Buy | Strong Buy |
11/3/2023 | Bloom Burton & Company | David Martin | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 10 |
Average Target Price | $15.78 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 77 of 252 |
Current Quarter EPS Est: | -0.16 |